Literature DB >> 32226620

Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma.

Syed Irfan-Ur Rahman1, Laura Nunez-Herrero1, Jamie Lee Berkes2.   

Abstract

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-reading-rahman a video presentation of this article.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID： 32226620      PMCID： PMC7098664          DOI： 10.1002/cld.908

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  11 in total

1.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

2.  Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients.

Authors:  Cigdem Soydal; Mustafa F Arslan; Ozlem N Kucuk; Ramazan Idilman; Sadik Bilgic
Journal:  Nucl Med Commun       Date:  2016-06       Impact factor: 1.690

3.  Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.

Authors:  T Kirchner; S Marquardt; T Werncke; M M Kirstein; T Brunkhorst; F Wacker; A Vogel; Thomas Rodt
Journal:  Abdom Radiol (NY)       Date:  2019-04

4.  International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.

Authors:  Jessica L Petrick; Megan Braunlin; Mathieu Laversanne; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2016-06-28       Impact factor: 7.396

Review 5.  Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.

Authors:  Nassir Rostambeigi; Adrienne S Dekarske; Erin E Austin; Jafar Golzarian; Erik N Cressman
Journal:  J Vasc Interv Radiol       Date:  2014-05-24       Impact factor: 3.464

6.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

7.  Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.

Authors:  Robert J Lewandowski; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald A Mora; Laura Kulik; Daniel Ganger; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Juan Carlos Caicedo; Michael Abecassis; Ahsun Riaz; Riad Salem
Journal:  Radiology       Date:  2018-04-24       Impact factor: 11.105

8.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization.

Authors:  Riad Salem; Margaret Gilbertsen; Zeeshan Butt; Khairuddin Memon; Michael Vouche; Ryan Hickey; Talia Baker; Michael M Abecassis; Rohi Atassi; Ahsun Riaz; David Cella; James L Burns; Daniel Ganger; Al B Benson; Mary F Mulcahy; Laura Kulik; Robert Lewandowski
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-02       Impact factor: 11.382

10.  Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.

Authors:  Jessica L Petrick; Scott P Kelly; Sean F Altekruse; Katherine A McGlynn; Philip S Rosenberg
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544
View more
  4 in total

Review 1.  Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma.

Authors:  Kylie E Zane; Paul B Nagib; Sajid Jalil; Khalid Mumtaz; Mina S Makary
Journal:  World J Hepatol       Date:  2022-05-27

Review 2.  Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.

Authors:  Valerie J W Tong; Vishal G Shelat; Yew Kuo Chao
Journal:  J Clin Transl Res       Date:  2021-11-06

3.  Xiaoai Jiedu Recipe suppresses hepatocellular carcinogenesis through the miR-200b-3p /Notch1 axis.

Authors:  Wenli Qiu; Zhongqiu Wang; Rong Chen; Haibo Shi; Yanxia Ma; Hongli Zhou; Muhan Li; Wenting Li; Haibin Chen; Hongguang Zhou
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

4.  Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma.

Authors:  Alexander Villalobos; William Wagstaff; Mian Guo; James Zhang; Zachary Bercu; Morgan J Whitmore; Mircea M Cristescu; Bill S Majdalany; Joel Wedd; Mehmet Akce; Joseph Magliocca; Nima Kokabi
Journal:  Can J Gastroenterol Hepatol       Date:  2021-07-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.